Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
On September 3, 2021, Insmed announced the granting of inducement awards to 18 new employees under NASDAQ Listing Rule 5635(c)(4).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
On September 3, 2021, Insmed announced the granting of inducement awards to 18 new employees under NASDAQ Listing Rule 5635(c)(4). Each employee received options to purchase a total of 394,730 shares at an exercise price of $29.13 per share, matching the closing price on September 1, 2021. The options come with a ten-year term and a four-year vesting schedule, with 25% vesting after the first year. Insmed focuses on treating serious and rare diseases with a robust therapy pipeline alongside its first-in-disease product approved in multiple regions.
Positive
- Attracting talent through stock options can enhance company performance.
- The options granted align employee interests with shareholder value.
Negative
- None.
Details
News Market Reaction – INSM
The recorded move for INSM in the trading session of this news was -2.50%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., Sept. 3, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 18 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
In connection with the commencement of their employment, the employees received options on September 1, 2021 to purchase an aggregate 394,730 shares of Insmed common stock at an exercise price of
The options have a ten-year term and a four-year vesting schedule, with
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a growing footprint across Europe and in Japan. For more information, visit www.insmed.com.
Contact:
Investors:
Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com
Media:
Mandy Fahey
Senior Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301368667.html
SOURCE Insmed Incorporated
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.